What total external‑beam radiation dose, brachytherapy boost dose, and concurrent chemotherapy regimen are recommended for definitive treatment of cervical cancer?

Radiation Dosing for Definitive Treatment of Cervical Cancer

For definitive treatment of intact cervical cancer, deliver approximately 45 Gy (40-50 Gy) external beam radiation therapy (EBRT) to the pelvis followed by a brachytherapy boost of 30-40 Gy to point A (LDR equivalent), achieving a total point A dose of 80 Gy for small-volume tumors or ≥85 Gy for larger-volume tumors, with concurrent weekly cisplatin 40 mg/m² throughout EBRT. 1

External Beam Radiation Therapy (EBRT) Dosing

The standard EBRT dose is 45 Gy delivered in 25 fractions at 1.8-2.0 Gy per daily fraction to the whole pelvis 1. This covers:

• Primary tumor and regional lymphatics at risk
• Parametria, uterosacral ligaments
• Presacral nodes
• External iliac, internal iliac, and obturator nodal basins

Field extension depends on nodal involvement:

• Negative nodes: Cover low true pelvis nodes only
• Higher risk or bulky tumors: Extend to common iliacs
• Para-aortic involvement: Extended-field radiation up to renal vessels 1

Nodal boost considerations:

• Grossly involved unresected nodes may receive an additional 10-15 Gy of highly conformal EBRT 1
• Use CT-based treatment planning with conformal blocking as standard 1

Brachytherapy Boost Dosing

Critical component: Brachytherapy is essential for definitive therapy and cannot be routinely replaced by EBRT alone 1

Low-Dose Rate (LDR) Brachytherapy

• Deliver 30-40 Gy to point A (at 40-70 cGy/h) 1
• Combined with EBRT for total point A dose:
  • 80 Gy for small-volume cervical tumors
  • ≥85 Gy for larger-volume cervical tumors 1, 2, 1

High-Dose Rate (HDR) Brachytherapy Conversion

The most common HDR approach uses 5 insertions with tandem and colpostats, each delivering 6 Gy to point A 1:

• Total HDR dose: 30 Gy in 5 fractions
• This equals approximately 40 Gy LDR equivalent to point A 1, 2, 1
• Use linear-quadratic model for dose conversions

Important caveat: When using image-guided brachytherapy, take care not to underdose tumors relative to traditional point A system recommendations 1

Concurrent Chemotherapy Regimen

Standard regimen: Cisplatin-based chemotherapy concurrent with EBRT significantly improves local control (Level A evidence) and overall survival (Level B evidence) 3

Primary Options:

1. Cisplatin 40 mg/m² weekly (preferred) 3, 4

   • Given throughout EBRT duration
   • Typically 5-6 cycles

2. Cisplatin/5-FU combination (acceptable alternative) 3, 4

   • Cisplatin 50-75 mg/m² every 3-4 weeks
   • 5-FU 4 g/m² over 4 days

Evidence note: Cisplatin alone appears equivalent to cisplatin/5-FU combinations, but with less toxicity (Level B-C evidence) 3. The cisplatin/5-FU/hydroxyurea combination shows greater toxicity than cisplatin alone without clear additional benefit 3.

Chemotherapy Timing

• Administer concurrent with EBRT (not with brachytherapy alone)
• Continue throughout external beam treatment course
• Chemotherapy is given during EBRT, with brachytherapy typically initiated toward the latter part of treatment 1

Treatment Sequencing

Two acceptable approaches 3:

1. Initial EBRT to total pelvis (minimum 40 Gy) → brachytherapy
2. Lower-dose EBRT → brachytherapy → lateral pelvic boost

Critical timing: Total treatment duration (EBRT + brachytherapy) should be less than 8 weeks 3

Posthysterectomy Adjuvant Dosing

For patients with pathologic risk factors after hysterectomy:

• 45-50 Gy in standard fractionation to vaginal cuff (upper 3-4 cm), parametria, and adjacent nodal basins 1
• Grossly involved unresected nodes: additional 10-15 Gy conformal boost 1
• Vaginal cylinder brachytherapy may be added for positive margins 1

Common Pitfalls to Avoid

1. Do not substitute EBRT for brachytherapy in intact cervix patients—brachytherapy is essential for adequate central disease control 1

2. Avoid underdosing with image-guided techniques—maintain point A dose equivalents even when using modern 3D planning 1

3. Limit normal tissue in high-dose regions—especially with EBRT doses >50 Gy, carefully exclude or severely limit bowel, bladder, and rectum volumes 1

4. Monitor treatment duration—prolonged overall treatment time (>8 weeks) may compromise outcomes 3

5. Toxicity considerations: Concurrent chemoradiotherapy increases bone marrow and gastrointestinal toxicity compared to radiation alone (Level B evidence) 3, requiring careful monitoring and supportive care